KR20210037581A - 항-클라우딘-3 키메라 항원 수용체 - Google Patents

항-클라우딘-3 키메라 항원 수용체 Download PDF

Info

Publication number
KR20210037581A
KR20210037581A KR1020200124522A KR20200124522A KR20210037581A KR 20210037581 A KR20210037581 A KR 20210037581A KR 1020200124522 A KR1020200124522 A KR 1020200124522A KR 20200124522 A KR20200124522 A KR 20200124522A KR 20210037581 A KR20210037581 A KR 20210037581A
Authority
KR
South Korea
Prior art keywords
ser
cells
gly
claudin
leu
Prior art date
Application number
KR1020200124522A
Other languages
English (en)
Korean (ko)
Inventor
신영기
김성수
양호빈
이지혜
이. 그래햄 티모시
로사 데 아라우호 파트리씨아
Original Assignee
(재)록원바이오융합연구재단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (재)록원바이오융합연구재단 filed Critical (재)록원바이오융합연구재단
Publication of KR20210037581A publication Critical patent/KR20210037581A/ko

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643Vertebrate antigens
    • A61K39/4644Cancer antigens
    • A61K39/464402Receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/461Cellular immunotherapy characterised by the cell type used
    • A61K39/4611T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/461Cellular immunotherapy characterised by the cell type used
    • A61K39/4613Natural-killer cells [NK or NK-T]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/463Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631Chimeric Antigen Receptors [CAR]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/7051T-cell receptor (TcR)-CD3 complex
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596Molecules with a "CD"-designation not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0646Natural killers cells [NK], NKT cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020200124522A 2019-09-26 2020-09-25 항-클라우딘-3 키메라 항원 수용체 KR20210037581A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20190118962 2019-09-26
KR1020190118962 2019-09-26

Publications (1)

Publication Number Publication Date
KR20210037581A true KR20210037581A (ko) 2021-04-06

Family

ID=75165906

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020200124522A KR20210037581A (ko) 2019-09-26 2020-09-25 항-클라우딘-3 키메라 항원 수용체

Country Status (2)

Country Link
KR (1) KR20210037581A (fr)
WO (1) WO2021060914A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024513713A (ja) * 2021-03-19 2024-03-27 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド クローディン-3を標的とするキメラ抗原受容体および癌を治療する方法
CN114478802B (zh) * 2022-01-28 2023-05-26 郑州大学 一种嵌合抗原受体及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5632582B2 (ja) * 2006-12-14 2014-11-26 中外製薬株式会社 抗Claudin3モノクローナル抗体およびそれを用いる癌の治療および診断
KR101334207B1 (ko) * 2011-02-09 2013-11-29 (주)레퍼런스바이오랩 복합 막횡단 단백질의 세포막외 펩타이드 항원 및 그의 용도
MX2016005763A (es) * 2013-11-06 2016-08-19 Stemcentrx Inc Anticuerpos anti-claudina novedosos y metodos de uso.
KR102055936B1 (ko) * 2017-09-20 2019-12-16 에이비온 주식회사 클라우딘 3 및 4에 대한 단일클론항체 및 그의 용도
KR102340989B1 (ko) * 2018-03-28 2021-12-20 에이비온 주식회사 클라우딘 3의 ecl-2에 특이적으로 결합하는 항체, 이의 단편 및 이들의 용도

Also Published As

Publication number Publication date
WO2021060914A1 (fr) 2021-04-01

Similar Documents

Publication Publication Date Title
CN100360565C (zh) 制备脊椎动物淋巴细胞和生产结合蛋白的方法
CN108822217A (zh) 一种基因碱基编辑器
CN113930455A (zh) Crispr寡核苷酸和基因剪辑
AU2020207840A1 (en) Rna-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
EP2921500B1 (fr) Lignes de cellules tueuses naturelles humaines modifiées génétiquement
KR20210037581A (ko) 항-클라우딘-3 키메라 항원 수용체
US6737241B2 (en) Methods for screening for transdominant intracellular effector peptides and RNA molecules
CN111511903A (zh) 用于改善的免疫细胞疗法的nk抑制剂基因的靶向基因整合
AU2016264323A1 (en) Compositions and methods for TCR reprogramming using fusion proteins
CN107108707A (zh) 高亲和力pd‑1药剂以及使用方法
KR20130027579A (ko) 세포 배양으로부터 수명 및 단백질 수율을 증가시키기 위한 개선된 방법 및 조성물
RU2770002C2 (ru) Химерный антигенный рецептор
KR102412805B1 (ko) 세포 면역 요법을 위한 조성물 및 방법
CN109652380B (zh) 基于碱基编辑靶向LewisY的CAR-T细胞及其制备方法和应用
CN113710697A (zh) 嵌合衔接子和激酶信号传导蛋白及其在免疫疗法中的用途
CA2443437A1 (fr) Anticorps specifiques contre cd44v6
CN117545765A (zh) 嵌合抗原受体t细胞
KR102178022B1 (ko) Fgf21 반응성 리포터 유전자 세포주
CN114134141B (zh) 一种引入非天然氨基酸的嵌合体苯丙氨酸翻译系统及其构建方法
KR20120108013A (ko) 형질전환 비-인간 동물 및 그것의 용도
CN110922484B (zh) 抗EGFRvIII抗体及其在疾病诊断或治疗中的应用
CN116640226B (zh) 一种抑制宿主抗外源免疫细胞hvg反应的嵌合受体
CN117769566A (zh) 嵌合抗原受体t细胞
CN117751181A (zh) 嵌合抗原受体t细胞
WO2024026127A2 (fr) Entités de liaison par affinité ciblées sur cd70 et leurs procédés d'utilisation

Legal Events

Date Code Title Description
A201 Request for examination